In 2017, the US FDA approved nivolumab as the first PD-1 checkpoint inhibitor for the adjuvant treatment of patients with melanoma with lymph node involvement or in patients with metastatic disease who had undergone complete resection. This evidence concerns the gene PDCD1 and melanoma.